InSite Vision Inc.’s drug delivery system has received a patent from the U.S. Patent and Trademark Office.
Alameda, CA-InSite Vision Inc.’s drug delivery system has received a patent from the U.S. Patent and Trademark Office.
The patent will provide utility-composition of matter protection until 2029 for InSite Vision’s DuraSite 2 for both its delivery system and drugs.
The drug delivery system provides a platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience.
“Based on its ability to improve drug retention and penetration (significantly) into the tissues of the eye, we believe (the drug delivery system) could serve as a standard drug delivery technology across ophthalmic therapeutics,” said Timothy Ruane, chief executive officer of InSite Vision. “We plan to utilize the . . . platform in the development of all future InSite Vision pipeline products and seek partners via licensing agreements.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.